In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on CVRx (CVRX – Research Report), with a price target of $35.00. The company’s shares closed yesterday at $25.93.
Takkinen covers the Healthcare sector, focusing on stocks such as NeuroPace, Apyx Medical, and Artivion. According to TipRanks, Takkinen has an average return of 9.6% and a 39.74% success rate on recommended stocks.
Currently, the analyst consensus on CVRx is a Strong Buy with an average price target of $34.00, implying a 31.12% upside from current levels. In a report released on January 26, Canaccord Genuity also maintained a Buy rating on the stock with a $32.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $33.14 and a one-year low of $6.57. Currently, CVRx has an average volume of 162.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CVRx (CVRX) Company Description:
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases.
Read More on CVRX:
- CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer
- 3 Best Stocks to Buy Now, 1/29/2024, According to Top Analysts
- CVRx price target raised to $32 from $31 at Canaccord
- CVRx price target raised to $33 from $21 at Piper Sandler
- CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
